FOR PARTICIPANTS: Important information about ASPREE-XT and COVID-19 In light of easing of restrictions in some locations, we are pleased to be able to resume face-to-face annual study visits in many parts of south eastern Australia. In-person study visits will be subject to advice from the Department of Health in your state or territory…
Details
Statins may prevent heart attacks and strokes but may not prolong life free of disability A new observational study shows the first-line cholesterol-lowering drugs known as statins are associated with fewer heart attacks and strokes, but not associated with a prolonged life free of physical disability or dementia in healthy older people. The study…
Details
ASPREE’s sub-study, ASPREE-D (depression) publishes findings on effect of daily low dose aspirin on prevention of depression. PRESS RELEASE: 4th June 2020 – Taking low dose aspirin daily does not prevent depression in healthy older adults, according to collaborative researchers at the Institute for Mental and Physical Health and Clinical Translation (IMPACT) and the ASPREE (ASPirin in Reducing Events in the Elderly) Clinical Trial.
Details
Landmark trial shows aspirin does not prevent cognitive decline in healthy elderly PRESS RELEASE: 1st April 2020 – Melbourne Researchers at Monash University and the Berman Center for Outcomes and Clinical Research in the US, have found that daily aspirin does not reduce the risk of Alzheimer’s disease, mild cognitive impairment, or cognitive decline…
Details
FOR PARTICIPANTS: Important information about ASPREE-XT and the Coronavirus (COVID-19) In light of public health recommendations to help slow the spread of Coronavirus (COVID-19) in the community, ASPREE-XT will be temporarily replacing annual face-to-face study visits with a phone call. This decision, which took effect as of Monday 23rd March 2020, will continue until further notice.…
Details
IT’S A WRAP FOR 2019! While we’d say that all study-related news and events were important, the most significant was the welcomed mid-year announcement that the NIA (National Institute on Aging) in the US would be funding the follow-up ASPREE-XT (eXTension) study for a further five years. Funding has ensured that our participants can…
Details
Impact of ASPREE trial on public health recognised. ASPREE researchers acknowledge the contribution of participants, GPs and fellow team members to the world-first trial. We are pleased to share details and photos of three Australian research awards recently won by the ASPREE study for its significance to public health. Monash University Dean’s Award…
Details
Landmark study to assess long-term health risks and benefits of prior aspirin use in elderly Landmark ASPREE study extended for five years to track study participants for long-term health outcomes after discontinuing aspirin. ASPREE-XT will investigate the long-term health in people over 70 (65 years in the US) following conclusion of ASPREE (low dose…
Details
Thanks to the American College of Cardiology, we are pleased to share this physician-penned article on the importance of the ASPREE study and the implications that study findings have on healthcare of older people around the world. The ASPREE Aftermath: A Geriatric Perspective on the Role of Aspirin in Older Adults Oct 11,…
Details
Welcome to our US NCI colleagues ASPREE investigators welcomed members from the National Cancer Institute (NCI) to the School of Public Health and Preventive Medicine, Monash University late last month. The NCI, a branch of the National Institutes of Health in the USA, funds ACES, the ASPREE Cancer Endpoints Study to better understand the…
Details© 2019 All Rights Reserved. • Monash University, Department of Epidemiology and Preventive Medicine | Disclaimer & Privacy